Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of TMS for treatment-resistant major depressive disorder
2025-521166-95-00Phase 2Authorised
- Sponsor
- Maastricht University
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and treatment-resistant depression (TRD) comparing D-cycloserine + transcranial magnetic stimulation with Placebo + transcranial magnetic stimulation (2 arms). Primary endpoint: Percentage reduction from baseline MADRS score. Planned start Jun 2025; status: authorised.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2025-521166-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521166-95-00.